Dipyridamole for coronary artery bypass surgery.

[1]  R. Weisel,et al.  Dipyridamole preserved platelets and reduced blood loss after cardiopulmonary bypass. , 1988, The Journal of thoracic and cardiovascular surgery.

[2]  R. Weisel,et al.  Improving myocardial metabolic and functional recovery after cardioplegic arrest. , 1988, The Journal of thoracic and cardiovascular surgery.

[3]  R. Weisel,et al.  Blood conservation with membrane oxygenators and dipyridamole. , 1987, The Annals of thoracic surgery.

[4]  A. Schmaier,et al.  Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. , 1987, The American journal of physiology.

[5]  L. Mickleborough,et al.  Increased risk of urgent revascularization. , 1987, The Journal of thoracic and cardiovascular surgery.

[6]  R. Weisel,et al.  Cardiac release of prostacyclin and thromboxane A2 during coronary revascularization. , 1987, The Journal of thoracic and cardiovascular surgery.

[7]  R. Weisel,et al.  Prevention of myocardial platelet deposition and thromboxane release with dipyridamole. , 1986, Circulation.

[8]  C. Higgins,et al.  Magnetic resonance imaging of cardiac transplants: the evaluation of rejection of cardiac allografts with and without immunosuppression. , 1986, Circulation.

[9]  L. Harker.  Bleeding after cardiopulmonary bypass. , 1986, The New England journal of medicine.

[10]  R. Colman,et al.  Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation. , 1985, The Journal of laboratory and clinical medicine.

[11]  A. Rimm.  Trends in cardiac surgery in the United States. , 1985, The New England journal of medicine.

[12]  S. Houle,et al.  A clinical trial of blood and crystalloid cardioplegia. , 1984, The Journal of thoracic and cardiovascular surgery.

[13]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, The Journal of thoracic and cardiovascular surgery.

[14]  S. Levitsky,et al.  Cardioplegia does not prevent reperfusion injury induced by intracoronary platelet deposition. , 1983, Circulation.

[15]  S. Levitsky,et al.  Platelet deposition after surgically induced myocardial ischemia. An etiologic factor for reperfusion injury. , 1982, The Journal of thoracic and cardiovascular surgery.

[16]  E. Genton,et al.  Platelet Release and Thromboxane Synthesis in Symptomatic Coronary Artery Disease , 1982, Circulation.

[17]  V. Fuster,et al.  A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. , 1982, The New England journal of medicine.

[18]  R. Colman,et al.  Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. , 1982, The Journal of thoracic and cardiovascular surgery.

[19]  E. Frenkel,et al.  Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. , 1981, The American journal of cardiology.

[20]  D. Stroncek,et al.  Complement activation and neutropenia occurring during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.

[21]  E. Salzman,et al.  Circulating Platelet Products in Unstable Angina Pectoris , 1981, Circulation.

[22]  E. Salzman,et al.  Elevated Plasma Fibrinopeptide A ana Thromboxane B2 Levels During Cardiopulmonary Bypass , 1980, Circulation.

[23]  J. Cooper,et al.  Pulmonary Leukostasis and Its Relationship to Pulmonary Dysfunction in Sheep and Rabbits , 1980, Circulation research.

[24]  R. Colman,et al.  Thromboxane synthesis and platelet secretion during cardiopulmonary bypass with bubble oxygenator. , 1980, The Journal of thoracic and cardiovascular surgery.

[25]  P. Henson,et al.  Biologial effects of the human complement fragments C5a and C5ades Arg on neutrophil function. , 1980, Immunopharmacology.

[26]  R. Colman,et al.  Effects of prostaglandin E1 on platelet loss during in vivo and in vitro extracorporeal circulation with a bubble oxygenator. , 1979, The Journal of thoracic and cardiovascular surgery.

[27]  T. Martin,et al.  Mode of action of dipyridamole on human platelets. , 1979, Thrombosis research.

[28]  P. Needleman,et al.  Coronary tone modulation: formation and actions of prostaglandins, endoperoxides, and thromboxanes. , 1977, Science.

[29]  F. Bachmann,et al.  The hemostatic mechanism after open-heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. , 1975, The Journal of thoracic and cardiovascular surgery.

[30]  S. Pfueller,et al.  Studies of the mechanisms of the human platelet release reaction induced by immunologic stimuli. I. Complement-dependent and complement-independent reactions. , 1974, Journal of immunology.

[31]  R. Dutton,et al.  Platelet aggregate emboli produced in patients during cardiopulmonary bypass with membrane and bubble oxygenators and blood filters. , 1974, The Journal of thoracic and cardiovascular surgery.

[32]  J. Smith,et al.  The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets. , 1971, The Biochemical journal.

[33]  P. Ashmore,et al.  The importance of microembolism in the pathogenesis of organ dysfunction caused by prolonged use of the pump oxygenator. , 1966, The Journal of thoracic and cardiovascular surgery.

[34]  A. J. Honour,et al.  Effect of dipyridamole on human platelet behaviour. , 1965, Lancet.